Starting July 1, 2026, millions of Medicare beneficiaries will have access to weight loss medications like Wegovy and Zepbound for a fixed $50 monthly copay through a new federal demonstration program called the Medicare GLP-1 Bridge. For people who have been paying more than $1,000 a month for these drugs out of pocket, the savings could be dramatic.
But the program comes with limitations that many enrollees may not fully understand before signing up — and for the lowest-income seniors, those limitations may make the program less accessible than the headline number suggests.
Why This Matters
GLP-1 medications have been transformational for people with obesity and obesity-related conditions. Semaglutide and tirzepatide — the active ingredients in Wegovy and Zepbound — have demonstrated weight loss of 15 percent to 22 percent in clinical trials and are associated with reductions in cardiovascular risk. Yet Medicare has never covered these drugs for weight loss. This is the first time it will.
However, the GLP-1 Bridge is a temporary demonstration, not a permanent benefit. People who start these medications now face real uncertainty about what happens in 2028 — and research consistently shows that most people who stop taking GLP-1 medications regain a significant portion of the weight they lost.
According to a KFF analysis, 56 percent of GLP-1 users reported these drugs were difficult to afford, including one in four who called them "very difficult." The Bridge addresses that barrier — but with important constraints.
What We Know So Far
According to the Centers for Medicare and Medicaid Services, the Medicare GLP-1 Bridge will run from July 1, 2026, to December 31, 2027. Eligible beneficiaries enrolled in a standalone Medicare Part D plan or a Medicare Advantage plan with drug coverage will pay $50 per month for covered GLP-1 medications.
The three drugs covered are: Wegovy (all formulations), Foundayo (all formulations), and Zepbound (KwikPen formulation only). The single-dose vial and single-dose pen formulations of Zepbound are not included.
To qualify, a beneficiary must meet at least one of the following clinical criteria: a BMI of 35 or higher; a BMI of 30 or higher with a diagnosis of heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher with a history of pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
Manufacturers have agreed to provide these medications at a net price of $245 per month to the government. The program is being administered through a central processor — not through individual Part D plans — meaning your plan does not need to opt in for you to access the Bridge.
The Fine Print Every Enrollee Needs to Know
This is where the GLP-1 Bridge diverges from how most Medicare drug benefits work — in ways that matter financially.
The $50 copay does not count toward your annual out-of-pocket cap. According to CMS and KFF, because the Bridge operates entirely outside the Part D benefit structure, the $50 monthly payment does not count toward the Part D deductible or the $2,100 annual out-of-pocket maximum. This means that every other covered medication you take under Part D still counts toward your cap — but not your GLP-1.
Low-income seniors cannot use Extra Help for Bridge costs. The Low-Income Subsidy program — also called Extra Help — normally reduces prescription costs for eligible low-income Medicare beneficiaries to very low levels. However, the LIS does not apply to the GLP-1 Bridge. This means the $50 monthly copay is fixed — even for seniors living on Social Security alone.
The program ends December 31, 2027. What happens next is uncertain. The Bridge is designed to lay the groundwork for a follow-on program called the BALANCE Model, but that model's implementation in Medicare Part D in 2028 remains contingent on plan participation and regulatory decisions that have not yet been finalized. CMS has already delayed the 2027 launch of the Medicare Part D portion of the BALANCE Model. As KFF notes: "It is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027."
Additional coupons and discounts cannot reduce the $50 copay. Manufacturer savings programs, discount apps, and GoodRx-type tools cannot be applied to Bridge claims.
Where the Access Gaps Are Largest
Low-income Medicare beneficiaries face the sharpest tension. A $50 monthly copay is $600 per year — and for a senior on a fixed income who qualifies for Extra Help because their monthly income is near the poverty level, that sum may represent a meaningful share of their discretionary health spending.
As KFF noted: "This may make it more difficult for low- and modest-income beneficiaries who are otherwise eligible to participate to take advantage of coverage under the short-term demonstration in 2026 and 2027 if the $50 monthly copayment is unaffordable."
For seniors in communities with higher rates of obesity and cardiovascular disease — including low-income urban and rural populations across the South, Midwest, and inland West — this limitation could undercut the program's reach precisely where it is most needed.
What Doctors and Experts Say
Health policy analysts at KFF, the Medicare Rights Center, and Sheppard Mullin have all noted the same core concern: the structure of the GLP-1 Bridge creates a transition cliff at the end of 2027 that may leave patients without coverage for medications they depend on for chronic disease management.
Physicians prescribing GLP-1 medications for appropriate patients are being advised by CMS to attest to the patient's clinical eligibility at the time therapy was first initiated — even if that was before the Bridge launched. This means patients who began Wegovy or Zepbound before July 1 may be eligible to transition to the Bridge without restarting the prior authorization clock.
Providers are also being reminded that the prior authorization process runs through a central processor — not the patient's individual Part D plan — and that the plan does not need to be involved.
What the Evidence Shows — and What It Does Not
The GLP-1 Bridge is a demonstration program, not a permanent benefit. CMS has said one goal of the Bridge is to collect data on GLP-1 utilization to share with Part D plan sponsors ahead of potential permanent implementation through the BALANCE Model. Whether the BALANCE Model will proceed as designed — and whether it will achieve sufficient plan participation to provide continuous coverage in 2028 — remains to be seen.
The clinical evidence supporting GLP-1 medications for obesity is well-established. The program's design, however, introduces financial and administrative uncertainty that patients and prescribers need to plan around.
Who Faces the Greatest Risk?
- Low-income seniors who qualify for Extra Help but find $50 per month unaffordable
- Seniors enrolled in plan types that are not eligible for the Bridge, including private fee-for-service plans, PACE organizations, and certain group waiver plans
- Patients who start the medication now and face an uncertain coverage path after December 31, 2027
- Seniors whose Part D plan participates or does not participate in the future BALANCE Model during the 2026 Open Enrollment period
What You Can Do Now
- Confirm that you are enrolled in an eligible plan type. The Bridge applies to standalone Part D plans and Medicare Advantage plans with drug coverage. Some plans, including private fee-for-service plans, are not eligible.
- Confirm your clinical eligibility with your doctor before July 1. The prior authorization request must go through the central GLP-1 Bridge processor, not your Part D plan.
- If you receive Extra Help, ask your doctor and pharmacist whether the $50 monthly copay is manageable given your income. If it is not, discuss alternatives, including Part D-covered GLP-1 drugs for type 2 diabetes, if that applies to you.
- Plan now for what happens after December 31, 2027. The 2026 Medicare Open Enrollment runs October 15 to December 7. Your plan's participation in the future BALANCE Model matters for continued access.
- Visit Medicare.gov/glp1bridge or call 1-800-MEDICARE to learn more and check your eligibility.
What Happens Next
The Bridge launches July 1, 2026. CMS will continue releasing implementation guidance through the summer. Medicare Open Enrollment — where seniors need to consider whether their plan will participate in the future BALANCE Model — runs October 15 to December 7, 2026. The BALANCE Model's status in Medicare Part D for 2028 remains uncertain. MedicalDaily will track program enrollment data and coverage transition developments.
The Bottom Line
The Medicare GLP-1 Bridge offers real financial relief for many Medicare beneficiaries who need these medications and could not previously afford them. But the program has meaningful limitations — especially for low-income seniors, who cannot use Extra Help for Bridge copays — and the road to continued coverage after 2027 is uncertain. Before enrolling, seniors should understand the fine print, confirm their plan eligibility, and start planning now for the 2026 Open Enrollment period.
References
- CMS — Medicare GLP-1 Bridge Program Page
- KFF — What to Know About the BALANCE Model and Medicare GLP-1 Bridge
- Medicare Rights Center — GLP-1 Weight Loss Drug Demonstration Begins July 2026
- Medicare Interactive — Medicare's GLP-1 Bridge Program
- Sheppard Mullin — Medicare's $50 Per Month GLP-1 Bridge: What You Need to Know
